Conversation with The Cancer Letter Goldwater’s Coleman: Right to Try patients don’t need permission from feds to save their own lives March 23, 2018Vol.44 No.12By Matthew Bin Han Ong
Conversation with The Cancer Letter NYU’s Caplan: Right to Try laws are meaningless, empty hot air, unethical, and utterly ineffective March 23, 2018Vol.44 No.12By Matthew Bin Han Ong
Conversation with The Cancer LetterFree Porter: I can’t tell you how the Trump administration gets its budget numbers March 16, 2018Vol.44 No.11By Paul Goldberg
Conversation with The Cancer Letter Basch: Patient-reported outcomes data can make cancer drugs safer, more tolerable March 16, 2018Vol.44 No.11By Matthew Bin Han Ong
Conversation with The Cancer LetterFree BMS’s Farajallah: Opdivo is the only PD-1 inhibitor approved for four-week dosing March 09, 2018Vol.44 No.10By Matthew Bin Han Ong
Conversation with The Cancer LetterFree PH.AI CEO Hyde: With Big Data, pharma will focus on the measurement of value March 02, 2018Vol.44 No.09By Matthew Bin Han Ong
Conversation with The Cancer LetterFree Roche CEO O’Day: Our investment in Flatiron will accelerate their mission March 02, 2018Vol.44 No.09By Matthew Bin Han Ong
Conversation with The Cancer LetterFree UT Health San Antonio’s link with MD Anderson goes live; How does it work? February 23, 2018Vol.44 No.08By Paul Goldberg
Conversation with The Cancer LetterFree His six-month “listening tour” almost over, Sharpless discusses his vision for NCI February 23, 2018Vol.44 No.08By Paul Goldberg
Conversation with The Cancer Letter NTRI’s Abrams: Smokers should use e-cigarettes if they can’t quit completely February 09, 2018Vol.44 No.06By Matthew Bin Han Ong
